CALAN SR (verapamil hydrochloride) by Pfizer is mechanism of action essential hypertension verapamil exerts antihypertensive effects by decreasing systemic vascular resistance, usually without orthostatic decreases in blood pressure or reflex tachycardia; bradycardia (rate less than 50 beats/min) is uncommon (1. First approved in 1986.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
CALAN SR is an extended-release oral formulation of verapamil hydrochloride, a calcium channel blocker approved in 1986. It treats essential hypertension, angina (including vasospastic/Prinzmetal's angina), and certain arrhythmias by reducing systemic vascular resistance and inhibiting calcium influx through slow channels. The drug dilates coronary and peripheral arteries, decreases afterload, and slows AV node conduction.
Product faces imminent loss of exclusivity with minimal Part D volume; brand team focus shifting to generic defense or niche positioning.
Mechanism of action Essential hypertension Verapamil exerts antihypertensive effects by decreasing systemic vascular resistance, usually without orthostatic decreases in blood pressure or reflex tachycardia; bradycardia (rate less than 50 beats/min) is uncommon (1.4%). During isometric or dynamic…
Worked on CALAN SR at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moCALAN SR offers limited career advancement due to its LOE-approaching status and minimal linked job opportunities. Roles are largely defensive and cost-focused; professionals should expect limited resources, team downsizing, and transition planning toward newer pipeline assets or generic optimization.